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Abstract
Background: Surgeons in the Netherlands, Canada and the US participate in the FAITH trial (Fixation using
Alternative Implants for the Treatment of Hip fractures). Dutch sites are managed and visited by a financed central
trial coordinator, whereas most Canadian and US sites have local study coordinators and receive per patient
payment. This study was aimed to assess how these different trial management strategies affected trial
performance.
Methods: Details related to obtaining ethics approval, time to trial start-up, inclusion, and percentage completed
follow-ups were collected for each trial site and compared. Pre-trial screening data were compared with actual
inclusion rates.
Results: Median trial start-up ranged from 41 days (P25-P75 10-139) in the Netherlands to 232 days (P25-P75 98-
423) in Canada (p = 0.027). The inclusion rate was highest in the Netherlands; median 1.03 patients (P25-P75 0.43-
2.21) per site per month, representing 34.4% of the total eligible population. It was lowest in Canada; 0.14
inclusions (P25-P75 0.00-0.28), representing 3.9% of eligible patients (p < 0.001). The percentage completed follow-
ups was 83% for Canadian and Dutch sites and 70% for US sites (p = 0.217).
Conclusions: In this trial, a central financed trial coordinator to manage all trial related tasks in participating sites
resulted in better trial progression and a similar follow-up. It is therefore a suitable alternative for appointing these
tasks to local research assistants. The central coordinator approach can enable smaller regional hospitals to
participate in multicenter randomized controlled trials. Circumstances such as available budget, sample size, and
geographical area should however be taken into account when choosing a management strategy.
Trial Registration: ClinicalTrials.gov: NCT00761813
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Background
Randomized controlled trials (RCTs) are generally per-
ceived as the reference standard for generating valid
scientific evidence on the evaluation of medical treat-
ments and interventions [1]. Unfortunately, RCTs con-
tinue to be relatively scarce in the orthopedic trauma
literature [2]. This may be attributed to the logistical
challenges of the implementation of RCTs.
One of the most apparent challenges of RCTs is to
recruit the required number of patients as timely and
efficiently as possible [3]. Availability of fewer patients
than expected usually leads to an extended trial period
and increased costs. Multicenter collaborations offer the
potential of recruiting more patients within a shorter
time period, which can be advantageous if large patient
numbers are required or if the targeted population has a
low incidence. They also have the advantage of
increased generalizability of the results [4,5]. However,
the conduct of multicenter clinical trials requires a
* Correspondence: e.vanlieshout@erasmusmc.nl
1Dept. of Surgery-Traumatology, Erasmus MC, University Medical Center
Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, the Netherlands
Full list of author information is available at the end of the article
Zielinski et al. Trials 2012, 13:5
http://www.trialsjournal.com/content/13/1/5 TRIALS
© 2012 Zielinski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
complex organization, which applies even more to inter-
national trials [6,7].
Obtaining ethics or Institutional Review Board (IRB)
approval is a potential cause of delay, as procedures,
documents, and legislation may vary between countries
[8]. This process is often time-consuming and it is
recommended to have dedicated and well-trained study
personnel available to assist participating sites with
these administrative tasks [9-13].
Another challenge in multicenter research is the selec-
tion and recruitment of appropriate participating clinical
sites. Every participating site should have a devoted and
dedicated clinician as site principal investigator. As sur-
geons often lack the time to spend on research, it is
important to have an assisting research team that can
adopt many of the time consuming research tasks. Hav-
ing adequate support can be more important for sites to
decide to participate, than offering a financial compen-
sation for participation [14,15]. The presence of a trial
coordinator or assistant will also facilitate an appropriate
study infrastructure, which is a requirement for proper
study conduct [3,8,16-18]. As community hospitals gen-
erally lack such infrastructure, they often cannot partici-
pate in multicenter trials. This is unfortunate, as some
injuries or interventions are much more frequent in
community hospitals than in university hospitals. Their
participation in a multicenter trial could therefore posi-
tively influence the recruitment rate. Once a large multi-
center or multinational RCT has started, a relatively
complex organization should be implemented and main-
tained in order to assure a complete patient follow-up
and a high quality in data management [19,20].
Usually individual sites are required to manage their
local ethics procedures and trial logistics. They generally
receive per patient payments as compensation. As an
alternative option, a single trial coordinator can be
appointed to manage all trial-related tasks for multiple
sites in a certain geographic area or country, in which
travel time is limited and does not include air fares.
This is dependent on availability of full financial sup-
port, but can relieve local sites from many trial related
tasks. This may attract more sites to participate, provide
a smoother process of obtaining ethics approval, quicker
trial start-up, higher inclusion rates and follow-up
completeness.
Similar management strategies have been applied in
the FAITH trial (Fixation using Alternative Implants for
the Treatment of Hip fractures, NCT00761813). The
FAITH trial is an international multicenter study
initiated by the IHFRC (International Hip Fracture
Research Collaborative) [21]. The primary objective of
this trial is to assess the impact of sliding hip screws
versus cancellous screw fixation on rates of revision sur-
gery at two years in elderly patients with femoral neck
fractures. This trial has been launched in over 60 sites,
predominantly situated in the Netherlands, Canada, and
the US. All sites in the Netherlands are managed and
visited by a single financed national trial coordinator.
Most Canadian and US sites have individual local site
coordinators and receive per patient payments. The aim
of this study was to assess how these strategies affected
performance of the FAITH trial.
Methods
Study Characteristics
In the Netherlands 14 hospitals participated in the
FAITH trial. In Canada 11 hospitals participated, and in
the US 29. Besides patient enrolment, sites were also
required to register all patients that were excluded or
missed for inclusion.
In the period before the trial started 26 of the partici-
pating Dutch, Canadian and US sites started prospective
screening for patients during a short defined period to
explore the amount and rate of potential inclusions that
could be expected from each site. The results of this
prospective screening study were used for the further
planning of the definitive trial.
Two different strategies were applied for the organi-
zation and management of the FAITH trial in these
participating countries. In the Netherlands the trial
was coordinated and managed from a university hospi-
tal. One central, national trial coordinator was
appointed upon obtaining adequate funding. This was
a medical doctor working on her PhD project. This
coordinator was responsible for all study related tasks
at all fourteen participating sites. She arranged the
process of ethics approval and the necessary docu-
ments for all sites, initiated study start-up, maintained
communication with sites and the methods center,
randomized all patients, and collected all follow-up
data for 250 patients. During a period when study
related tasks became too much to handle for a single
person, she was assisted by the research team at the
central coordinating site. There was no local research
support at the participating sites. The coordinator tra-
velled regularly to all participating sites, which were
within a range of maximum 114 kilometers from the
coordinating site. Participating sites were only respon-
sible for patient selection. Sites received no payment;
all funding was used for covering costs of the central
trial coordination.
Most Canadian and US sites (located in various states
ranging from Nova Scotia to British Columbia and from
California to New York) were responsible themselves for
all local study related tasks. The vast majority of these
sites have individual, local, research assistants that take
care of these tasks for the FAITH trial, as well as for
other trials in that hospital. As compensation these sites
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receive per patient payment. In these countries there
was no central, national trial coordinator.
All countries were supervised by the FAITH trial cen-
tral methods center and steering committee. In order to
monitor progress and to keep participating sites focused,
there was contact between the methods center and the
Dutch central coordinator, Canadian and US local prin-
cipal investigators on a weekly base. The Dutch central
coordinator had weekly contact with the participating
sites and all sites received monthly newsletters showing
the progress of the trial.
Data
Data related to trial initiation, organization, and perfor-
mance were collected up to August 11, 2010. At this
time patient recruitment was still ongoing in Canada
and the US. Data were collected concerning:
- baseline characteristics; country, type of hospital (i.e.,
university, non-university teaching, or non-university non-
teaching), type of research coordinator (i.e., not available,
site-specific or provided for by central coordinating site);
- process of obtaining ethics approval; submission and
approval date, number of submissions and type of revi-
sions (i.e., changes in wording or content of the
informed consent form, changes in in- or exclusion cri-
teria, changes in the wording or content of the study
protocol, extra information on the study protocol and
procedures, extra information on financial aspects, or
request for additional documents);
- pre-trial screening period; screening start and stop
date, total number of patients screened and number of
eligible patients screened;
- trial period: trial start and (if applicable) stop dates,
total number of included, excluded and missed patients
that were registered, total number of patients that were
missed for registration (for the Netherlands only), total
amount of kilometers travelled by research coordinator
and associated costs (for the Netherlands only), follow-
up completeness.
Additional variables that were calculated from these
data are described in Table 1.
Data Analysis
All analyses were conducted using SPSS (version 16.0,
SPSS Inc., Chicago, IL, USA). Data from the three coun-
tries (the Netherlands, Canada and US) were compared.
The choice to compare these three countries was made
because of the differences in trial management between the
Netherlands and Canada/US described above. Comparing
these countries separately also allowed the possibility to
study country related differences that may affect trial per-
formance, independent from the trial management strategy
chosen. Continuous variables are presented as median with
interquartile ranges. Categorical variables are presented as
number (percentage). Continuous variables were compared
with the Kruskal-Wallis Analysis of Variance (ANOVA).
Post-hoc pair wise comparisons were performed using the
Mann-Whitney U-test. Categorical variables were com-
pared with the Chi-squared test. A P-value < 0.05 (two-
sided) was taken as threshold of statistical significance.
Results
Characteristics of participating sites
The type of hospitals participating was similar for the
Netherlands (NL), Canada (CA) and the US (Table 2).
All sites in the Netherlands were centrally coordinated,
whereas local site coordination was available at 72.7% of
Canadian sites and 96.6% of US sites.
Table 1 Additional variables calculated concerning the period of obtaining ethics approval and the screening and trial
period
Variable Calculation
Time necessary for ethics/IRB approval (days) a - b
Time between ethics/IRB approval and start trial (days) c - a
Screening period (days) f - e
Enrolment/trial period (days) d - c
Total number of patients in screening period (n per month) g/(f - e)
Number of eligible patients in screening period (n per month) h/(f - e)
Proportion eligible patients of total in screening period (%) (h/g) * 100
Total number of patients per month in trial period (n per month) (i + j)/(d - c)
Number of inclusions in trial period (n per month) i/(d - c)
Proportion inclusions of total in trial period (%) (i/(i + j)) * 100
Proportion patients that were missed for registration in trial period of total (%) (k/(i + j + k)) * 100
Rate of total number of patients per month in trial period versus screening period ((i + j)/(d - c))/(g/(f - e))
Rate of number of inclusions/eligible patients per month in trial period versus screening period (i/(d - c))/(h/(f - e))
Rate of percentage inclusions/eligible patients per month in trial period versus screening period ((i/(i + j) * 100)/((h/g) * 100)
a, ethics/IRB approval date; b, ethics/IRB submission date; c, trial start date; d, trial stop date; e, screening start date; f, screening stop date; g, total number of
patients screened; h, number of eligible patients screened; i, number of inclusions; j, number of excluded or missed patients that were registered; k, number of
patients that were missed for registration.
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Process of obtaining ethics/IRB approval
The time necessary for ethics/IRB approval was signifi-
cantly longer in the Netherlands (median 104 days) than
in Canada (median 55 days) and the US (median 53
days; p = 0.027; Table 3). For all countries the median
number of submissions requested by the ethics commit-
tee was one. However, due to the differences in data dis-
tribution and skewness there was still a significant
difference in requested submissions between NL (P25-
P75 0.0-1.0) and the US (P25-P75 1.0-3.0) (p = 0.014).
The type of revisions requested did not differ between
the countries; the vast majority concerned wording and
content of the informed consent form.
Pre-trial screening period
Of the currently participating FAITH sites four Dutch,
eight Canadian, and fourteen US sites also took part in
the pre-trial prospective screening period. The duration
of the screening period did not differ significantly
between groups (Table 4). The number of patients
screened per site was least in the Netherlands with six
patients in total and 3.3 patients per month. Forecasted
total number of patients was highest for Canadian sites
with 15 patients per site in total and 7.5 per month (p =
0.006 and p = 0.016). Other variables, concerning the
amount and proportion of eligible patients screened,
were not significantly different between countries.
Trial period
Dutch hospitals started enrolment in the period between
February 2008 and October 2008. In August 2009 the
national goal of enrolling 250 patients was achieved.
Canadian hospitals started enrolment between March
2008 and June 2010. In the US hospitals started
Table 2 Characteristics of countries participating in the FAITH trial
NL
(N = 14)
CA
(N = 11)
US
(N = 29)
P-value
Type of hospital
University 4 (28.6) 9 (81.8) 16 (55.2) 0.051
Non-university teaching 10 (71.4) 2 (18.2) 11 (37.9)
Non-university non-teaching 0 (0.0) 0 (0.0) 2 (6.9)
Trial coordinator
Not available 0 (0.0) 0 (0.0) 1 (3.4) < 0.001
Available at site 0 (0.0) 8 (72.7) 28 (96.6)
Provided by central coordinating site 14 (100.0) 3 (27.3) 0 (0.0)
NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites participating per country.
Data are presented as numbers with percentage between brackets. Statistics were calculated using the Chi-squared test.
Table 3 Data concerning the process of obtaining ethics/IRB approval of countries participating in the FAITH trial
NL
(N = 14)
CA
(N = 11)
US
(N = 19)
P-value
Time necessary for ethics/IRB approval1 (days) 104
(74-135)
55
(27 - 77)
53
(44 - 105)
0.027+ a
Revision rounds1 1 (0.0 - 1.0) 1 (0.8 - 1.0) 1 (1.0 - 3.0) 0.014+ b
Type of revisions requested:
Wording of IC Form2 6 (42.9) 5 (50.0) 12 (66.7) 0.382++
Content of IC Form2 6 (42.9) 5 (50.0) 8 (44.4) 0.938++
In- or exclusion criteria2 0 (0.0) 1 (10.0) 1 (5.3) 0.511++
Wording of study protocol2 0 (0.0) 1 (10.0) 0 (0.0) 0.185++
Content of study protocol2 1 (7.1) 2 (20.0) 1 (5.3) 0.406++
Additional information in study protocol/procedures2 5 (35.7) 3 (30.0) 7 (36.8) 0.932++
Financial aspects -
Request for extra information2
0 (0.0) 1 (10.0) 3 (15.8) 0.303++
Request additional documents2 2 (14.3) 0 (0.0) 3 (15.8) 0.421++
NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites per country for which data were available.
IC, informed consent form.
1 Data are presented as median with P25-P75 given between brackets.
2 Data are presented as number with percentages.
+ Kruskal-Wallis ANOVA, ++ Chi-squared test
Post-hoc pair wise comparisons were performed using the Mann-Whitney U-test: a Statistical significance was reached when comparing NL vs. CA (p = 0.025),
and NL vs. US (p = 0.019), CA vs. US: not significant. b Statistical significance was reached when comparing NL vs. US (p = 0.007), other groups: not significant
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enrolment between February 2009 and September 2010.
In Canada and the US enrolment is still ongoing.
The time necessary for trial start-up was defined as
the time between obtained ethics approval and the
actual trial start up. With a median of 41 days, trial
start-up was fastest for the Netherlands. Trial start-up
took more than five times longer for Canada (median
232 days; p = 0.027; Table 5). Because the median enrol-
ment period was statistically significantly longer for the
US than for the Netherlands (median 283 vs. 423 days,
respectively, p = 0.001), crude numbers were also calcu-
lated per month. The total number of patients seen per
month in the trial period was similar in all countries;
however, the inclusion rate in the Dutch sites per
month was more than three times higher than in the US
sites, and more than seven times higher compared with
Canadian sites (1.03 patients per month vs. 0.31 and
0.14, respectively, p < 0.001). Inclusion progression of
all countries is also shown in Figure 1. Similar differ-
ences were seen when comparing the proportion inclu-
sions of the total patient group. In Dutch sites 34.4% of
the patients were included vs. 16.7% in US sites and
3.93% in Canadian sites (p = 0.001). These numbers
may however be influenced by the varying screening
compliance in all countries. For example, sites screening
all hip fractures would certainly have greater screening
failure rates then those sites screening only those hip
fractures that were deemed treatable by internal fixation.
For sites in the Netherlands data were extracted from
hospital records in order to check for omissions in
Table 4 Data concerning the pre-trial screening period of countries participating in the FAITH trial
NL
(N = 4)
CA
(N = 8)
US
(N = 14)
P-value
Screening period (days) 55 (51 - 92) 60 (56 - 74) 50 (20 - 69) 0.121
Eligible patients (N) 4 (3 - 6) 4 (1 - 10) 3 (1 - 6) 0.571
Total patients (N) 6 (6 - 9) 15 (15 - 34) 6 (5 - 11) 0.006a
Eligible patients (N per month) 2.0 (1.7 - 2.4) 1.5 (0.7 - 4.1) 2.2 (1.1 - 5.0) 0.786
Total patients (N per month) 3.3 (3.0 - 3.6) 7.5 (5.6 - 17.4) 5.0 (3.1 - 8.2) 0.016 b
Proportion eligible patients (% of total) 63 (53 - 67) 14 (10 - 40) 48 (29 - 71) 0.062
NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites per country that data were available for.
Data are presented as median with P25-P75 given between brackets.
Statistics were calculated using the Kruskal-Wallis ANOVA.
Post-hoc pair wise comparisons were performed using Mann-Whitney U-test: a Statistical significance was reached when comparing NL vs. CA (p = 0.009), and CA
vs. USA (p = 0.004), NL vs. USA: not significant. b Statistical significance was reached when comparing NL vs. CA (p = 0.007), other groups: not significant.
Table 5 Data concerning the trial period of countries participating in the FAITH trial
NL
(N = 14)
CA
(N = 11)
US
(N = 29)
P-value
Time between ethics approval and start trial (days) 41 (10 - 139) 232 (98 - 423) 87 (45 - 255) 0.027a
Enrolment period (days) 423 (381 - 509) 482 (267 - 663) 283 (142 - 360) 0.001b
Inclusions 13 (7 - 27) 3 (0 - 5) 3 (1 - 6) < 0.001c
Registered patients 23 (12 - 36) 54 (3 - 75) 16 (5 - 27) 0.060
Patients missed for registration1 35 (10 - 81) Unknown Unknown
Inclusions (n per month) 1.03 (0.43 - 2.21) 0.14 (0.00 - 0.28) 0.31 (0.09 - 0.62) < 0.001d
Total patients (n per month) 2.49 (1.60 - 3.64) 2.76 (0.60 - 8.75) 1.96 (1.11 - 3.75) 0.574
Proportion inclusions (% of total) 34.4 (23.8 - 62.6) 3.93 (0.00 - 13.2) 16.7 (2.50 - 31.3) 0.001e
Proportion patients that were missed for registration of total1 (%) 57.4 (32.2 - 65.2) Unknown Unknown
Completed follow-ups (%) 82.6 (80.0 - 84.6) 83.5 (72.7 - 95.2) 70.0 (60.0 - 88.1) 0.217
Follow-ups in window (%) 77.1 (71.0 - 82.2) 85.9 (81.0 - 95.0) 85.7 (70.0 - 100.0) 0.073
NL, the Netherlands; CA, Canada; US, United States.
Numbers in the headers represent the number of sites per country that data were available for.
Data are presented as median with P25-P75 given between brackets.
Statistics were calculated using the Kruskal-Wallis ANOVA.
1 Data available for NL only.
Post-hoc pair wise comparisons were performed using a Mann-Whitney U-test: a Statistical significance was reached when comparing NL vs. CA (p = 0.010), other
groups: not significant. b Statistical significance was reached when comparing NL vs. US (p < 0.001), other groups: not significant. c Statistical significance was
reached when comparing NL vs. CA (p = 0.002) and NL vs. US (p < 0.001), CA vs. US: not significant. d Statistical significance was reached when comparing NL vs.
CA (p = 0.001) and NL vs. US (p = 0.001), CA vs. US: not significant. e Statistical significance was reached when comparing NL vs. CA (p < 0.001) and NL vs. US (p
= 0.009), CA vs. US: not significant.
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patient registrations during the trial. A median of 35
excluded and missed patients (P25-P75 10-81) were not
registered per site, despite clear instructions to partici-
pating sites that this was required for the trial. This
represented 57.4% of the total amount of patients seen
during the trial period. These data were not available for
the other countries.
Follow-up data were collected at eight time points,
four times in clinic and four times by telephone. The
percentage completed follow-ups were calculated for all
time points and the overall percentage completed fol-
low-ups was computed. The median overall percentage
completed follow-ups was 70% in Canada, and exceeded
80% in the Netherlands and US. No statistically signifi-
cant differences were found between countries (Table
5). The median percentage of follow-ups that were com-
pleted within the predefined acceptable time window
was 77% in the Netherlands, and 86% in Canada and
the US. Again, this was not statistically significantly dif-
ferent (Table 5).
During this study, the central trial coordinator in the
Netherlands travelled 28,842 kilometers in order to visit
all fourteen participating sites for trial start-up, enrol-
ment, and data collection in clinic. This resulted in €
9,771 total travel costs.
Pre-trial screening period versus trial period
Pre-trial screening data regarding eligible patients were
compared with the actual inclusion rates and percen-
tages in the trial period, to study the value of pre-trial
screening data. An overview of the calculated variables
is shown in Table 1. Inclusion rates in the trial were
much lower than expected from the screening period: a
decline of 67% (P25-P75 42-83) was noted for sites in
the Netherlands versus a decline of 92% (P25-P75 78-
100) for US and 93% (P25-P75 68-100) for Canadian
sites (p = 0.154; Figure 2). The total number of patients
seen in the trial period versus the screening period also
displayed a decline: 41% less (P25-P75 -2-62) for the
Netherlands versus 52% (P25-P75 9-88) for Canada and
69% (P25-P75 35-81) for the US (p = 0.477). Conse-
quently, the proportion inclusions of the total patient
group also decreased: 48% decrease (P25-P75 14-69) for
sites in the Netherlands versus 83% (P25-P75 39-100)
for Canadian sites and 83% (P25-P75 56-100) for US
sites (p = 0.091).
Discussion
In this study, trial progression in the Netherlands, where
a central trial coordinator managed most tasks for mul-
tiple centers in a restricted geographical area, was better
than in Canada and the US, where local research assis-
tants were appointed at individual sites. The central trial
coordinator system was associated with a shorter trial
start-up time, higher inclusion rate, and a higher inclu-
sion percentage. Collection of follow-up data was
equally good in both systems.
The process of obtaining ethics approval can be time-
consuming and stressful and may yield diverse responses
from ethics committees [9-13]. For the FAITH trial,
obtaining ethics approval took longer in the Netherlands
than in Canada or the US. This may have been influ-
enced by the time that the trial coordinator or sites
needed to assemble forms for the ethics committee.
Figure 1 Inclusion progression for the Netherlands (NL), Canada (CA) and the United States (US).
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Ethics submissions may have taken longer in the Neth-
erlands at the very start of the trial, when there was no
central trial coordinator yet. The longer approval pro-
cess in the Netherlands may also have been caused by
more inefficient medical ethics procedures [10]. In the
Netherlands multicenter studies need approval from a
central ethics committee that performs a full review of
the study documents. Subsequently, ethics committees
in participating sites should only advise on local feasibil-
ity. This two-step approach was aimed to simplify and
shorten the ethics procedures for multicenter trials. It is
nevertheless disputable if this goal is currently achieved
[10]. In Canada and the US a single procedure for study
review and approval is performed at all sites, which may
turn out to be more efficient.
The number of resubmissions requested by the ethics
committees was lower in the Netherlands, and can
therefore not have contributed to the prolonged
approval process. The availability of a central trial coor-
dinator with detailed insight and knowledge on the
study content could have prevented incorrect submis-
sions in the Netherlands. In all countries remarks of the
ethics committees mainly involved the informed consent
form and extra information on the study protocol and
procedures. Standardization of the ethics approval pro-
cess is recommended as it may reduce the local differ-
ences in ethics approval terms.
The trial start-up period was statistically significantly
shorter in the Netherlands (median 41 days) than in the
US and Canada (87 and 232 days). In these latter two
countries contract negotiations with participating sites
had to take place during the trial start-up period,
whereas this procedure was not applicable in the Neth-
erlands. Furthermore, research assistants from Canada
and the US frequently reported a long period between
grant approval and official release of the funds. These
aspects related to the per patient payment strategy
applied in Canada and the US slowed the trial start-up
process in these countries. In the Netherlands contract
negotiations or per patient payments were unnecessary,
as all tasks were performed by the central study coordi-
nator, not resulting in delay. The assistance of the
Dutch central trial coordinator in trial start-up activities
(e.g. distributing study materials, giving start-up presen-
tations) may also have contributed to a more efficient
and speedy trial start-up.
Most influential to the differences in trial progression
between the countries were the evident differences in
inclusion rate and percentage, which were statistically
significantly higher for sites in the Netherlands. The
availability of the central trial coordinator in the Nether-
lands made it possible for smaller, non-university sites
without a local research infrastructure or coordinator to
participate. These sites generally treat more patients
from the targeted population (i.e., femoral neck fracture
patients) than the large university hospitals, but would
normally not have been able or willing to participate in
the trial, because they lack a local coordinator. Most of
the principal investigators of these sites reported to be
very motivated to enroll patients, as the (administrative)
Figure 2 The percentage decline in total number of patients seen per month, number of inclusions per month and percentage
inclusions of total number of patients, during the trial period in comparison with the pre-trial screening period. To calculate this
percentage decline, the total number of patients seen in the trial period was divided by the total number of patients seen in the pre-screening
trial period. Similar calculations were made for the number of inclusions per month and the inclusion percentage. These rates (a) were
transformed to a percentage decline (b) using the following formula: b = (1-a) * 100%. This figure therefore shows that for all variables there
were fewer patients during the trial period compared with the pre-trial screening period in all countries. NL, the Netherlands; CA, Canada; US,
United States.
Zielinski et al. Trials 2012, 13:5
http://www.trialsjournal.com/content/13/1/5
Page 7 of 11
burden of participation was relatively low, thanks to the
fact that the performance of follow-ups and other trial
related tasks were adopted by the central trial coordina-
tor. They declared that this was crucial in their decision
to participate. This high devotion and lack of burden-
some trial related tasks will probably have contributed
to a good inclusion rate. Therefore, the availability of a
central trial coordinator can contribute to a fast enrol-
ment, both directly, by motivating local principal investi-
gators to participate and enroll because of the low
(administrative) burden of participation, and indirectly,
by enabling high-volume hospitals without a local
research network to participate. However, differences in
accrual between countries may also have been affected
by the known intercultural differences in preferred treat-
ments for femoral neck fractures [22]. North American
surgeons may have considered less femoral neck fracture
patients suitable for internal fixation than Dutch sur-
geons do, as they are less committed to internal fixation
as a preferred treatment. Moreover, surgeons from the
US and Canada reported at investigator meetings that
North American patients may be less lenient to partici-
pate in trials and that they experienced problems at
obtaining informed consent [23]. Within the countries,
higher accrual was also associated with a large target
population, dedicated and compliant principal investiga-
tors, and low study related workload for participating
surgeons. These are important aspects to pursue when
planning a multicenter randomized controlled trial, and
can be facilitated by appointing a central trial
coordinator.
Comparison of the pre-trial prospective screening data
with the actual trial data showed an obvious discrepancy
in all countries. It is known that participating surgeons
tend to overestimate enrolment numbers based upon a
pre-trial screening period [24]. In this study accrual was
also much lower than expected from the screening per-
iod. The use of pre-trial screening can therefore be
debated. However, it may be useful to indicate good
dedication to participate and help raise awareness for
the upcoming study in potential sites. If a pre-trial
screening is deemed necessary, a retrospective approach
is recommended, as it is easier and results in similar
estimated numbers, compared with a prospective
approach [24].
The percentage completed follow-ups was not affected
by the availability of a central trial coordinator and was
between 70% and 84% for all countries. Follow-ups did
seem to be completed within the window a bit less in
the Netherlands, although not statistically significant.
This was a result of the limitations that we experienced
from the central trial coordinator approach. Usefulness
of this approach will decrease with an increased sample
size and an increased distance between sites. A single
person can only manage a certain maximum number of
sites and patients. Similarly, there is a maximum to the
distance that can be traveled per day. In our study, a
single study coordinator to manage 14 sites and 250
patients seemed somewhat limited. The study coordina-
tor had to complete eight follow-ups per patient (four
clinical and four telephonic), in 14 sites that were maxi-
mum 140 km. apart (maximum 2 hours travel time),
resulting in an average of almost 1,000 km traveled per
week. In these circumstances it was not always feasible
to manage all follow-ups. We feel that it would have
been optimal to have one coordinator following a maxi-
mum number of 200 patients, in our study. It is also
important to have a supporting research team available
for assistance if work pressure gets too high for a single
person. The central coordinator approach is feasible
within European countries, as well as within American/
Canadian states.
Finally, a central coordinator may also contribute to
the impartiality of the collected data and may prevent
biases that could be introduced if the local coordina-
tors/participating doctors are also the treating physician.
Obviously, this could not be analyzed or proven in this
study.
Obviously, this study has its limitations. Many of the
results of this study were multifactorially influenced.
Not all differences between countries can therefore be
attributed to the difference in trial management system.
If the two models (i.e., central management and local
management) would have been conducted equally in
each of the countries, bias due to country-specific con-
ditions could have been ruled out. This was however
impossible in the current study. Nevertheless, the avail-
ability of the central coordinator has certainly contribu-
ted to the speedier trial start-up, high enrolment rates
and complete follow-up. Also, the limited number of
sites available for data assemblage (especially for the
screening period) and the fact that not all data were col-
lected prospectively may have introduced some bias.
Conclusions
In summary, trial performance can be influenced by the
management strategy chosen. This study shows that the
appointment of a central financed trial coordinator to
manage all trial related tasks is a feasible alternative for
the more traditional approach of appointing trial related
tasks to local research assistants at participating sites.
Taking important circumstances such as available bud-
get, sample size, and geographical area into account, a
central trial coordinator approach can add to the suc-
cess of a multicenter randomized trial. A central coordi-
nator should be considered when studying injuries that
occur more frequently in smaller regional hospitals
(without a local research coordinator). It will enable
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these sites to participate in randomized controlled trials,
resulting in a enhanced enrolment rate. It should also
be considered when the targeted principal investigators
are unable to participate due to the (administrative) bur-
den of participation. However, a central coordinator
should only be considered for multiple sites in a
restricted geographical area. Depending upon the geo-
graphic spread of the sites and the frequency of follow-
up a careful estimation should be made of the amount
of patients and sites that can be managed by a single
coordinator.
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